Sr One Capital Management, Llc Acquires 126,315 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Key Points

• Sr One Capital Management acquired 126,315 shares of Zenas BioPharma at an average price of $19.00 per share, increasing their ownership to nearly 1.92 million shares.
• Zenas BioPharma's shares recently traded down 2.6% to $25.85, with a market capitalization of approximately $1.09 billion.
• Analysts have mixed ratings on Zenas BioPharma, with a consensus price target of $38.33 and varying recommendations from "buy" to "sell".

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) major shareholder Sr One Capital Management, Llc bought 126,315 shares of the business's stock in a transaction dated Thursday, October 9th. The shares were bought at an average price of $19.00 per share, with a total value of $2,399,985.00. Following the purchase, the insider owned 1,917,895 shares in the company, valued at $36,440,005. The trade was a 7.05% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Zenas BioPharma Stock Down 2.6%

Shares of NASDAQ ZBIO traded down $0.69 during mid-day trading on Tuesday, reaching $25.85. 415,023 shares of the company were exchanged, compared to its average volume of 207,008. The company's 50-day simple moving average is $19.06 and its 200-day simple moving average is $13.56. The stock has a market capitalization of $1.09 billion and a P/E ratio of -7.28. Zenas BioPharma, Inc. has a twelve month low of $5.83 and a twelve month high of $29.73.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23).

Institutional Investors Weigh In On Zenas BioPharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Federated Hermes Inc. lifted its position in Zenas BioPharma by 60.8% during the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company's stock worth $18,041,000 after purchasing an additional 703,838 shares during the period. Geode Capital Management LLC boosted its stake in shares of Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock valued at $3,621,000 after purchasing an additional 16,461 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Zenas BioPharma in the 1st quarter valued at approximately $348,000. Nuveen LLC acquired a new stake in shares of Zenas BioPharma in the 1st quarter valued at approximately $250,000. Finally, Rhumbline Advisers boosted its stake in shares of Zenas BioPharma by 71.3% in the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company's stock valued at $191,000 after purchasing an additional 8,207 shares in the last quarter.

Analysts Set New Price Targets

ZBIO has been the topic of several research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Zenas BioPharma in a research note on Wednesday, October 8th. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Zenas BioPharma in a research note on Thursday, October 9th. Wall Street Zen downgraded shares of Zenas BioPharma from a "hold" rating to a "sell" rating in a research note on Friday, September 26th. Finally, Wedbush upped their price target on shares of Zenas BioPharma from $35.00 to $40.00 and gave the company an "outperform" rating in a research note on Thursday, October 9th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.33.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.